Qiagen said today that the US Food and Drug Administration has extended the indications for use of its Therascreen EGFR RGQ PCR kit to guide the use of Boehringer Ingelheim’s Gilotrif (afatanib) for first-line treatment of patients with metastatic non-small cell lung cancer harboring non-resistant EGFR mutations.
{iframe}https://www.genomeweb.com/pcr/qiagen-gets-fda-ok-expanded-use-egfr-cdx-lung-cancer-drug?utm_source=Sailthru&utm_medium=email&utm_campaign=GWDN%20Fri%20AM%202018-01-19&utm_term=GW%20Daily%20News%20Bulletin{/iframe}